Acetoxy drug: Protein transacetylase catalyzed activation of human platelet nitric oxide synthase by polyphenolic peracetates

被引:43
作者
Khurana, P
Kumari, R
Vohra, P
Kumar, A
Seema
Gupta, G
Raj, HG [1 ]
Dwarakanath, BS
Parmar, VS
Saluja, D
Bose, M
Vij, A
Chaudhary, NK
Adhikari, JS
Tyagi, YK
Kohli, E
机构
[1] Univ Delhi, Vallabhbhai Patel Chest Inst, Dept Biochem, Delhi 110007, India
[2] DRDO, Inst Nucl Med & Allied Sci, Delhi, India
[3] Univ Delhi, Dept Chem, Delhi 110007, India
[4] Univ Delhi, Dr BR Ambedkar Ctr Biomed Res, Delhi 110007, India
[5] Univ Delhi, Vallabhbhai Patel Chest Inst, Dept Microbiol, Delhi 110007, India
[6] DRDO, Def Inst Physiol & Allied Sci, Delhi, India
关键词
nitric oxide; nitric oxide synthase; transacetylase; platelet aggregation; polyphenolic peracetate; protein acetylation;
D O I
10.1016/j.bmc.2005.08.044
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
An enhanced intracellular level of Nitric oxide (NO) is essential to ameliorate several pathological conditions of heart and vasculature necessitating the activation of NOS. We have projected in this report the acetylation of eNOS by polyphenolic peracetates (PA) catalyzed by the novel enzyme acetoxy drug: protein transacetylase (TAase) discovered in our laboratory as an unambiguous way of activating NOS which results in the manifestation of physiological action. The human platelet was chosen as the experimental system in order to validate the aforementioned proposition. PA caused profound irreversible activation of platelet NADPH cytochrome c reductase mediated by TAase. The convincing biochemical evidences are presented to show that PA could cause acetylation of the reductase domain of NOS leading to the activation of eNOS in tune with their specificities to platelet TAase. As a result, the enhanced level of NO due to activation of platelet eNOS by PA was found to inhibit the ADP-induced platelet aggregation. The present studies highlight for the first time the role of PA as the novel potent agent for enhancing the intracellular NO levels. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:575 / 583
页数:9
相关论文
共 30 条
[1]   Nitric oxide synthases: structure, function and inhibition [J].
Alderton, WK ;
Cooper, CE ;
Knowles, RG .
BIOCHEMICAL JOURNAL, 2001, 357 (03) :593-615
[2]   Activation of endothelial nitric-oxide synthase by tumor necrosis factor-α:: A novel pathway involving sequential activation of neutral sphingomyelinase, phosphatidylinositol-3′ kinase, and Akt [J].
Barsacchi, R ;
Perrotta, C ;
Bulotta, S ;
Moncada, S ;
Borgese, N ;
Clementi, E .
MOLECULAR PHARMACOLOGY, 2003, 63 (04) :886-895
[3]  
CAROL P, 2001, CELL, V107, P815
[4]   Functional consequences of endothelial nitric oxide synthase uncoupling in congestive cardiac failure [J].
Dixon, LJ ;
Morgan, DR ;
Hughes, SM ;
McGrath, LT ;
El-Sherbeeny, NA ;
Plumb, RD ;
Devine, A ;
Leahey, W ;
Johnston, GD ;
McVeigh, GE .
CIRCULATION, 2003, 107 (13) :1725-1728
[5]  
Gadre JN, 1996, INDIAN J CHEM B, V35, P60
[6]   Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1 [J].
GarciaCardena, G ;
Fan, R ;
Stern, DF ;
Liu, JW ;
Sessa, WC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (44) :27237-27240
[7]  
HABIG WH, 1974, J BIOL CHEM, V249, P7130
[8]  
HALPERT J, 1989, DRUG METAB DISPOS, V17, P26
[9]   COVALENT MODIFICATION OF LYSINE DURING THE SUICIDE INACTIVATION OF RAT-LIVER CYTOCHROME-P-450 BY CHLORAMPHENICOL [J].
HALPERT, J .
BIOCHEMICAL PHARMACOLOGY, 1981, 30 (08) :875-881
[10]  
HALPERT JR, 1986, MOL PHARMACOL, V30, P19